KANGGANRAN YAOXUE

Archive

  • 2023 Volume 20 Issue 1
    Published: 25 January 2023
      
  • Select all
    |
  • Research Progress in Effect and Mechanism of Honokiol against Glioma and Head-neck Tumors
    ZHANG Ming-fa, SHEN Ya-qin
    2023, 20(1): 1-5. https://doi.org/10.13493/j.issn.1672-7878.2023.01-001
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Honokiol, as one of main active ingredients of the traditional Chinese medicine Magnoliae Officinalis Cortex, has a wide range of pharmacological effects. In addition to antibacterial, anti-inflammatory, and anti-oxidative effects, it also has good pharmacological activity against glioma, nasopharyngeal carcinoma, tongue cancer, laryngeal cancer, etc. In this article, the pharmacological effects and mechanism of honokiol on glioma, nasopharyngeal carcinoma, tongue cancer, laryngeal cancer and other head-neck tumors are reviewed, and the related researches are analyzed.
  • Research Progress in Infection Characteristics of Monkeypox Virus and Killing Effect of Povidone-Iodine
    YUAN Guo-dong
    2023, 20(1): 6-8. https://doi.org/10.13493/j.issn.1672-7878.2023.01-002
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Since the extinction of smallpox virus in the 1980s, the active vaccination of smallpox vaccine has been stopped gradually in various countries of the world. However, monkeypox virus, a close relative of smallpox virus, has spread and transmitted in many countries in Africa. In recent years, a number of confirmed or suspected cases of monkeypox virus infection have been reported successively in countries outside Africa, which has aroused global concerns about the spread and prevalence of monkeypox virus infection in a wider scale. In this article, the transmission and infection characteristics of monkeypox virus and the killing effect of povidone-iodine on monkeypox virus are reviewed, and the related researches are analyzed.
  • Research on Quality Evaluation Method of Shengqing Qushi Decoction, a Hospital-made Preparation*1
    CHEN Tong, WAN Mei-ling, JIA Xian-hong, GUAN Cheng-zhen, GUO Lin
    2023, 20(1): 9-13. https://doi.org/10.13493/j.issn.1672-7878.2023.01-003
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To establish a quality evaluation method for Shengqing Qushi Decoction (SQD), a hospital-made preparation, and provide a reference for subsequent quality evaluation of the preparation. Methods: By using SQD as the test sample, puerarin and astragaloside IV standards as the reference substances, the puerarin content in SQD was determined by high performance liquid chromatography (HPLC), the content of astragaloside IV in SQD was determined by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS), and the prescription of ministerial drug (astragalus, bupleurum) in SQD was qualitatively identified by thin-layer chromatography (TLC). Results: The determination results by HPLC showed that the linear range of puerarin was 4.88-43.92 μg/mL, and the regression equation was ρpuerarin=42 692 A-10 100 (r=0.999 9); the determination results by HPLC-MS/MS showed that the linear range of astragaloside IV was 28-6 800 ng/mL, and the regression equation was ρastragaloside IV=6.31 A+12.60 (r=0.998 0); in addition, the precision test, repeatability test and spiked recovery test of the determination methods for the contents of puerarin and astragaloside IV were ideal; the average contents of puerarin and astragaloside IV in SQD were 0.152 3 mg/mL and 1 040.333 3 ng/mL respectively; the TCL result showed that the spots of traits of astragalus and bupleurum in SQD were clear. Conclusion: The determination of puerarin and astragaloside IV in SQD by HPLC and HPLC-MS/MS has good accuracy, precision, repeatability and stability, which can be used to perform the quantitative quality evaluation of SQD, while the TLC method can be used to perform the qualitative quality control of astragalus and bupleurum in SQD.
  • Pharmaceutical Care in Clinical Treatment of One Patient with Esophageal Perforation Complicated with Mediastinal Infection*1
    JIA Rong-di, XU Feng-lan, WANG Hua-jun
    2023, 20(1): 14-17. https://doi.org/10.13493/j.issn.1672-7878.2023.01-004
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To analyze the process and key points of pharmaceutical care in the clinical treatment of patients with esophageal perforation complicated with mediastinal infection, and provide reference for the implementation of pharmaceutical care for such patients. Methods and Results: In the clinical work, the clinical pharmacist found one patient with esophageal perforation and infection due to a foreign body entering the esophagus, who was then given conventional treatments such as anti-infection, acid suppression for stomach protection and rehydration support, but the anti-infective treatment effect of imipenem-cilastatin sodium was always not good; the clinical pharmacist repeatedly suggested to take purulent drainage fluid for microbial culture examination, and the physician finally accepted the suggestion, and Stenotrophomonas maltophilia was detected. Then the anti-infection treatment regimen was adjusted immediately according to the culture result and the drug susceptibility test results, finally the patient's infection symptoms and indicators were improved apparently. Conclusion: When clinical pharmacists perform pharmaceutical care for patients with esophageal perforation complicated with mediastinal infection, especially those with complex conditions, individualized analysis should be conducted actively to assist physicians to find the pathogen, and formulate a targeted treatment regimen to promote the rapid recovery of patients.
  • Analysis of Clinical Features of Adverse Drug Reactions Caused by Toripalimab*1
    CHEN Yu-ting, JING Tian-chuang, ZHAO Ming-yi
    2023, 20(1): 18-22. https://doi.org/10.13493/j.issn.1672-7878.2023.01-005
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To investigate the clinical features and rules of adverse drug reactions (ADRs) caused by toripalimab (TRPL) and provide reference for the safe use of the drug in clinical practice. Methods: 21 patients with ADRs caused by TRPL reported by the provincial medical institutions to the Henan Adverse Drug Reaction Monitoring Center as of September 2021 and 17 patients with ADRs caused by TRPL searched from the domestic and foreign literatures with the keywords such as "特瑞普利单抗", "不良反应", "病例”"toripalimab", "adverse reaction" and "case report" were selected, and the clinical features and rules of ADRs caused by TRPL were analyzed in terms of age, gender, drug dose, ADRs occurrence time, and organs involved, etc. Results: The relevance evaluation showed that, among the 38 cases of ADRs, 1 case (2.63%) was "definitely relevant" with TRPL, 22 cases (57.89%) were "probably relevant" with TRPL, and 15 cases (39.47%) were "possibly relevant" with TRPL; the 38 cases of ADRs caused by TRPL were mainly male patients (23 cases, 60.53%), and the age was mainly between 50+ and 80 years old (27 cases, 71.76%). Among the 38 cases, there were only 15 cases whose use of TRPL complied with the indications of the package insert, including 11 cases of malignant melanoma, and 4 cases of urothelial carcinoma. Among the 38 cases, the single dose of TRPL was mainly fixed at 240 mg (30 cases, 78.95%); ADRs caused by TRPL mainly occurred within 90 days after drug administration (30 cases, 78.95%), and the organs involved by ADRs were mainly the skin and its appendages (11 cases, 28.95%), endocrine system (10 cases, 26.32%) and digestive system (10 cases, 26.32%); after treatment, 31 of the 38 patients with ADRs were cured or improved (81.58%). Conclusion: TRPL is a newly marketed antineoplastic drug, and there are few reports on ADRs related to the drug. The clinical features of ADRs related to TRPL should be continuously observed and analyzed, so as to provide reference for its safe use in clinical practice.
  • Analysis of Drug Resistance of Tuberculosis Patients to 4 Common First-line Anti-tuberculosis Drugs in Xiamen from 2016 to 2020
    DONG Chun-ping, WU Ding-hui, YANG Ying-hui, YAO Xiang-yang
    2023, 20(1): 79-82. https://doi.org/10.13493/j.issn.1672-7878.2023.01-020
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To investigate the drug resistance of tuberculosis patients to 4 common first-line anti-tuberculosis drugs of isoniazid (INH), rifampin (RFP), streptomycin (SM) and ethambutol (EMB), and provide reference for anti-tuberculosis treatment of tuberculosis patients. Methods: A total of 2 126 tuberculosis patients admitted to the First Affiliated Hospital of Xiamen University from January 2016 to December 2020 were selected as the subjects, and the clinical data of patients such as gender, age, resistance to the four first-line anti-tuberculosis drugs (INH, RFP, SM and EMB) were collected, to investigate the current situation and characteristics of drug resistance of tuberculosis patients. Results: From 2016 to 2020, 531 of the 2 126 tuberculosis patients were resistant to first-line anti-tuberculosis drugs (the drug resistance rate was 24.98%), and the drug resistance rate fluctuated little in each year (P>0.05); among the 2 126 tuberculosis patients, the drug resistance rate of male patients to first-line anti-tuberculosis drugs was higher than that of female patients (26.32% vs 21.62, P<0.05); through comparison, there was a significant difference in the rate of drug resistance to first-line anti-tuberculosis drugs among tuberculosis patients at different ages (P<0.05), among which, the drug resistance rate was the highest in patients at 40+ to 60 years old (28.21%), and the drug resistance rate was the lowest in patients at no more than 20 years old (18.99%). Among the 531 drug-resistant tuberculosis patients, their drug resistance rates to INH and SM were high (15.67% and 15.29%, respectively), while their drug resistance rate to EMB was the lowest (4.61%). Among the 531 drug-resistant tuberculosis patients, the ratio of patients who were resistant to only one first-line anti-tuberculosis drug was the highest (48.59%), while the ratio of patients who were resistant to 3 or 4 drugs was low (17.70% and 12.05%, respectively). Among the 531 drug-resistant tuberculosis patients, the main drug-resistant types were monodrug-resistant tuberculosis (258 cases, 48.59%) and multidrug-resistant tuberculosis (214 cases, 40.30%). Among patients with monodrug-resistant tuberculosis, the drug resistance was mainly to SM (139 cases, 26.18%); among patients with multidrug-resistant tuberculosis, there were many patients who were resistant to INH+RFP+SM, INH+RFP+SM+EMB and INH+RFP, 69 cases (12.99%), 64 cases (12.05%) and 58 cases (10.92%) respectively. Conclusion: At present, the drug resistance of tuberculosis patients to the first-line anti-tuberculosis drugs is still in a severe situation in Xiamen, and the multidrug-resistance is serious. Clinical management of standardized treatment of tuberculosis patients should be further strengthened to reduce the occurrence of drug resistance as much as possible.